Kazutaka Shimbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazutaka Shimbo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Yutaka Matsuda
Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kanagawa 210-8681, Japan
5 shared publications - Natsuki Shikida
Ajinomoto (Japan)
4 shared publications - Takuya Seki
Ajinomoto (Japan)
4 shared publications - Akira Nakayama
Ajinomoto (Japan)
3 shared publications - Noriko Hatada
Ajinomoto (Japan)
3 shared publications - Tatsuya Okuzumi
Ajinomoto (Japan)
3 shared publications
Latest Publications
- Open Access
- 23 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody-Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of potent drug payloads. This study presents the development and evaluation of a novel exolinker designed to enhance ADC stability and pharmacokinetics by addressing the limitations associated with traditional cleavable linkers. Using trastuzumab conjugated with a payload linker consisting of an exo-linker and exo-EVC-Exatecan (APL-1082), we examined key parameters, including in vivo efficacy and pharmacokinetic profiles in rat models, to directly compare it with the clinically validated trastuzumab-deruxtecan (T-DXd, Enhertu). Our Exo-linker ADC demonstrated superior stability and maintained drug-to-antibody ratios (DAR) with reduced aggregation and hydrophobicity compared to T-DXd, suggesting an improved pharmacokinetic profile. Additionally, combining the Exo-linker with AJICAP site-specific conjugation technology enabled the production of high-DAR ADCs, achieving a DAR of 10 with promising homogeneity and physicochemical properties. Collectively, these findings underscore the potential of the exo-linker as a versatile platform for next-generation ADCs, offering enhanced stability, efficacy, and expanded therapeutic possibilities.
- 23 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBiological Evaluation of Cleavable Linkers in Exatecan-Based Antibody-Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of potent drug payloads. This study presents the development and evaluation of a novel exolinker designed to enhance ADC stability and pharmacokinetics by addressing the limitations associated with traditional cleavable linkers. Using trastuzumab conjugated with a payload linker consisting of an exo-linker and exo-EVC-Exatecan (APL-1082), we examined key parameters, including in vivo efficacy and pharmacokinetic profiles in rat models, to directly compare it with the clinically validated trastuzumab-deruxtecan (T-DXd, Enhertu). Our Exo-linker ADC demonstrated superior stability and maintained drug-to-antibody ratios (DAR) with reduced aggregation and hydrophobicity compared to T-DXd, suggesting an improved pharmacokinetic profile. Additionally, combining the Exo-linker with AJICAP site-specific conjugation technology enabled the production of high-DAR ADCs, achieving a DAR of 10 with promising homogeneity and physicochemical properties. Collectively, these findings underscore the potential of the exo-linker as a versatile platform for next-generation ADCs, offering enhanced stability, efficacy, and expanded therapeutic possibilities.
- Open Access
- 12 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Specific Antibody-Drug Conjugate Synthesis
A traceless site-selective conjugation method, “AJICAP-M,” was developed for native antibodies at specific sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios, enhanced stability, and simplified manufacturing. Comparative in vivo assessment demonstrated AJICAP-M's superior stability over traditional ADCs. This technology has been successfully applied to continuous-flow manufacturing, marking the first achievement in site-specific ADC production. This manuscript outlines AJICAP-M's methodology and its effectiveness in ADC production.
- 12 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Specific Antibody-Drug Conjugate Synthesis
A traceless site-selective conjugation method, “AJICAP-M,” was developed for native antibodies at specific sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios, enhanced stability, and simplified manufacturing. Comparative in vivo assessment demonstrated AJICAP-M's superior stability over traditional ADCs. This technology has been successfully applied to continuous-flow manufacturing, marking the first achievement in site-specific ADC production. This manuscript outlines AJICAP-M's methodology and its effectiveness in ADC production.
- Open Access
- 25 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Exo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Customized drug delivery systems have become paramount in the rapidly evolving field of precision medicine, and at the forefront of advances in this regard, antibody-drug conjugates (ADCs) present a symbiotic fusion of cytotoxic payloads and monoclonal antibodies (mAbs) facilitated by intricate chemical linkers. The search for ideal linkers that can dexterously provide the dual functionalities of enhancing circulatory stability and facilitating the effective release of the tumor payload is a present and formidable challenge. The valine-citrulline (Val-Cit) linker, which is used in a wide range of ADCs, despite its approval by the Food and Drug Administration, is associated with several inherent drawbacks, including hydrophobicity-induced aggregation, limited payload capacity, and premature payload release. This study presents a paradigm shift from the conventional linear linker archetype by introducing an exo-linker avant-garde approach that repositions the cleavable peptide linker at the exo-position of the PAB moiety. This molecular refinement not only offered the possibility to overcome the intrinsic drawbacks of the Val-Cit platform, but also significantly improved ADC stability, therapeutic efficacy, and pharmacokinetics. In vitro and in vivo biological evaluations, confirmed that ADCs designed using the exo-linker blueprint significantly attenuated premature payload release, while increasing the drug-to-antibody ratio, even with hydrophobic payloads, and this without inducing pronounced aggregation. Therefore, the fabricated exo-linker represents a significant improvement with respect to traditional Val-Cit ADCs. Moreover, under the influence of enzymes, such as carboxylesterases and human neutrophil elastase, the payload remained stably conjugated to the ADC, underscoring a favorable safety profile and highlighting potential for clinical translatability. Thus, our findings also demonstrate the potential of the novel exo-linker paradigm as well as the profound implications of nuanced molecular modifications for reshaping ADC design and functionality.
- 25 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessExo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Customized drug delivery systems have become paramount in the rapidly evolving field of precision medicine, and at the forefront of advances in this regard, antibody-drug conjugates (ADCs) present a symbiotic fusion of cytotoxic payloads and monoclonal antibodies (mAbs) facilitated by intricate chemical linkers. The search for ideal linkers that can dexterously provide the dual functionalities of enhancing circulatory stability and facilitating the effective release of the tumor payload is a present and formidable challenge. The valine-citrulline (Val-Cit) linker, which is used in a wide range of ADCs, despite its approval by the Food and Drug Administration, is associated with several inherent drawbacks, including hydrophobicity-induced aggregation, limited payload capacity, and premature payload release. This study presents a paradigm shift from the conventional linear linker archetype by introducing an exo-linker avant-garde approach that repositions the cleavable peptide linker at the exo-position of the PAB moiety. This molecular refinement not only offered the possibility to overcome the intrinsic drawbacks of the Val-Cit platform, but also significantly improved ADC stability, therapeutic efficacy, and pharmacokinetics. In vitro and in vivo biological evaluations, confirmed that ADCs designed using the exo-linker blueprint significantly attenuated premature payload release, while increasing the drug-to-antibody ratio, even with hydrophobic payloads, and this without inducing pronounced aggregation. Therefore, the fabricated exo-linker represents a significant improvement with respect to traditional Val-Cit ADCs. Moreover, under the influence of enzymes, such as carboxylesterases and human neutrophil elastase, the payload remained stably conjugated to the ADC, underscoring a favorable safety profile and highlighting potential for clinical translatability. Thus, our findings also demonstrate the potential of the novel exo-linker paradigm as well as the profound implications of nuanced molecular modifications for reshaping ADC design and functionality.
- 13 September 2023
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 415 (26) , 6461-6469
Analytical studies on the conjugation site specificity of trastuzumab modified by Escherichia coli lipoate ligase A: multiple-enzyme digestion approach for peptide mapping
Tag-free protein modification has received considerable attention in the field of chemical biology owing to the versatility and simplicity of the reaction sequence. In 2021, a novel tag-free enzymatic modification of antibodies utilizing lipoate ligase A (LplA) was reported to reveal its potential in the production of site-specific antibody conjugates. Primary peptide mapping analysis revealed the biased site specificity of antibodies modified by LplA; however, quantitative analysis remains challenging because of the complicated heterogeneity derived from biased selective modification. In an effort to further understand the site occupancy of LplA-modified antibodies, this study employed numerous unconventional techniques and strategies. Optimization of HPLC conditions and utilization of enzymes such as trypsin, Glu-C, and chymotrypsin significantly increased sequence data coverage. The transition from traditional spectral counting to a more accurate peak area–based label-free quantification helped better analyze peptide modification levels. The results obtained indicate that LplA-induced modifications are specific lysines, particularly the light chain Lys188/190 site, which have an increased modification rate compared to chemically induced modifications. This study not only contributes to the understanding of peptide modification, but also presents an improved methodology that promises to stimulate further research in this field. Graphical Abstract
- 13 September 2023
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 415 (26) , 6461-6469
Analytical studies on the conjugation site specificity of trastuzumab modified by Escherichia coli lipoate ligase A: multiple-enzyme digestion approach for peptide mapping
Tag-free protein modification has received considerable attention in the field of chemical biology owing to the versatility and simplicity of the reaction sequence. In 2021, a novel tag-free enzymatic modification of antibodies utilizing lipoate ligase A (LplA) was reported to reveal its potential in the production of site-specific antibody conjugates. Primary peptide mapping analysis revealed the biased site specificity of antibodies modified by LplA; however, quantitative analysis remains challenging because of the complicated heterogeneity derived from biased selective modification. In an effort to further understand the site occupancy of LplA-modified antibodies, this study employed numerous unconventional techniques and strategies. Optimization of HPLC conditions and utilization of enzymes such as trypsin, Glu-C, and chymotrypsin significantly increased sequence data coverage. The transition from traditional spectral counting to a more accurate peak area–based label-free quantification helped better analyze peptide modification levels. The results obtained indicate that LplA-induced modifications are specific lysines, particularly the light chain Lys188/190 site, which have an increased modification rate compared to chemically induced modifications. This study not only contributes to the understanding of peptide modification, but also presents an improved methodology that promises to stimulate further research in this field. Graphical Abstract
- Open Access
- 30 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community. We previously reported a unique site modification using a class of immunoglobulin-G (IgG) Fc-affinity reagents to establish a versatile, streamlined, and site-selective conjugation of native antibodies to enhance the therapeutic index of the resultant ADCs. This methodology, termed “AJICAP,” successfully modified Lys248 of native antibodies to produce site-specific ADC with a wider therapeutic index than the Food and Drug Administration-approved ADC, Kadcyla. However, the long reaction sequences, including the reduction-oxidation (redox) treatment, increased. In this manuscript, we aimed to present an updated Fc-affinity-mediated site-specific conjugation technology named “AJICAP second generation” without redox treatment utilizing a "one-pot” antibody modification reaction. The stability of Fc affinity reagents was improved owing to structural optimization, enabling the production of various ADCs without aggregation. In addition to Lys248 conjugation, Lys288 conjugated ADCs with homogenous drug-to-antibody ratio of 2 were produced using this technology after a proper modification of the spacer linkage of Fc-affinity peptide reagents. These two conjugation technologies were used to produce over 20 ADCs from several combinations of antibodies and drug linkers. The in vivo profile of Lys248 and Lys288 conjugated ADCs was also compared. Furthermore, non-traditional ADC applications, such as antibody-protein conjugates and antibody-oligonucleotide conjugates, were performed. These results strongly indicate that this Fc affinity conjugation approach is a promising strategy for manufacturing site-specific antibody conjugates.
- 30 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community. We previously reported a unique site modification using a class of immunoglobulin-G (IgG) Fc-affinity reagents to establish a versatile, streamlined, and site-selective conjugation of native antibodies to enhance the therapeutic index of the resultant ADCs. This methodology, termed “AJICAP,” successfully modified Lys248 of native antibodies to produce site-specific ADC with a wider therapeutic index than the Food and Drug Administration-approved ADC, Kadcyla. However, the long reaction sequences, including the reduction-oxidation (redox) treatment, increased. In this manuscript, we aimed to present an updated Fc-affinity-mediated site-specific conjugation technology named “AJICAP second generation” without redox treatment utilizing a "one-pot” antibody modification reaction. The stability of Fc affinity reagents was improved owing to structural optimization, enabling the production of various ADCs without aggregation. In addition to Lys248 conjugation, Lys288 conjugated ADCs with homogenous drug-to-antibody ratio of 2 were produced using this technology after a proper modification of the spacer linkage of Fc-affinity peptide reagents. These two conjugation technologies were used to produce over 20 ADCs from several combinations of antibodies and drug linkers. The in vivo profile of Lys248 and Lys288 conjugated ADCs was also compared. Furthermore, non-traditional ADC applications, such as antibody-protein conjugates and antibody-oligonucleotide conjugates, were performed. These results strongly indicate that this Fc affinity conjugation approach is a promising strategy for manufacturing site-specific antibody conjugates.
- 1 November 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 51, 128360
Lipoate-acid ligase a modification of native antibody: Synthesis and conjugation site analysis
- 1 November 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 51, 128360
Lipoate-acid ligase a modification of native antibody: Synthesis and conjugation site analysis